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INTRODUCTION
Angiogenesis is the production of new capillaries 
from a pre-existing vascular bed. It occurs physiologically 
during embryonic development, wound healing and in 
the female reproductive tract during the menstrual cycle 
[1, 2]. It is important in the proliferation and development 
of metastasis in solid malignancies, since without the 
formation of vessels to support the tumor, it does not 
grow more than 1 or 2 mm [3, 4]. Thus, inhibition of 
angiogenesis can suppress the growth and the potential 
of tumor invasion and it could be an important strategy 
in controlling malignancies [1, 5]. The study of tumor 
angiogenesis in hematologic malignancies, like non-
Hodgkin’s lymphomas (NHL), is a relevant issue to be 
explored, bringing new expectations to the therapeutic, 
and mostly, to the evolution of the patients who suffer 
from this prevalent neoplasia.
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ABSTRACT
Despite advances in treatment, 30% of diffuse large B-cell lymphoma (DLBCL) 
cases are refractory or relapse after chemoimmunotherapy. Currently, the relationship 
between angiogenesis and angiomiRs in DLBCL is unknown. We classified 84 DLBCL 
cases according to stromal signatures and evaluated the expression of pro- and 
antiangiomiRs in paraffin embedded tissues of DLBCL and correlated them with 
microvascular density (MVD). 40% of cases were classified as stromal-1, 50% 
as stromal-2 and 10% were not classified. We observed increased expression of 
proangiomiRs Let-7f, miR-17, miR-18a, miR-19b, miR-126, miR-130a, miR-210, miR-
296 and miR-378 in 14%, 57%, 30%, 45%, 12%, 12%, 56%, 58% and 48% of the 
cases, respectively. Among antiangiomiRs we found decreased expression of miR-16, 
miR-20b, miR-92a, miR-221 and miR-328 in, respectively, 27%, 71%, 2%, 44% and 
11%. We found association between increased expression of proangiomiRs miR-126 
and miR-130a and antiangiomiR miR-328 and the subtype non-GCB. We found higher 
levels of the antiangiomiRs miR-16, miR-221 and miR-328 in patients with low MVD 
and stromal-1 signature. IPI and CD34 confirmed independent impact on survival 
of the study group. None of the above angiomiRs showed significance as biomarker 
in an independent serum samples cohort of patients and controls. In conclusion, 
we confirmed association between antiangiomiRs miR-16, miR-221 and miR-328 
and stromal-1 signature. Four angiomiRs emerged as potential therapeutic targets: 
proangiomiRs miR-17, miR-210 and miR-296 and antiangiomiR miR-20b. Although the 
four microRNAs seem to be important in DLBCL pathogenesis, they were not predictive 
of DLBCL onset or relapse in the serum independent cohort.
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MicroRNAs (miRNAs) are a class of highly 
conserved non-coding RNAs, with around 20-22 
nucleotides. They have been described as regulators of 
encoding protein genes and some of them have a role in 
the control of many aspects of angiogenesis [6, 7]. The 
identification of these miRNAs has opened new paths in 
the therapeutic of vascular and oncologic diseases, since 
they are candidates to target specific therapies [6, 7]. In 
this study we extended one former endeavor [8, 9] and 
evaluated the expression of angiogenesis-related miRNAs 
in paraffin embedded tissues of diffuse large B-cell 
lymphomas (DLBCL). DLBCL constitute the majority 
of the diagnosed patients with B-NHL and it can be used 
as a model to explore the angiogenesis as a therapeutic 
target for other types of lymphomas. Besides, we intended 
to explore the importance of the tumor microenvironment 
and to classify DLBCL cases according to the prognostic 
signatures described in 2008 by Lenz et al. [10], i.e., 
stromal-1 and stromal-2. The stromal-1 signature reflects 
the extracellular matrix deposition, while the stromal-2 
signature represents tumors with higher MVD.
Currently, DLBCL cases show favorable response 
to standard immunochemotherapy (R-CHOP - rituximab, 
cyclophosphamide, doxorubicin, vincristine and 
prednisone). However, 10%-15% of the patients will be 
primarily refractory to this treatment and around 20%-25% 
will relapse after the initial response [11, 12]. Therefore, 
one third of the DLBCL cases who do not respond to the 
standard therapy need a different approach. The combined 
analysis of the angiogenesis process in DLBCL using 
the expression of the proteins related to the stromal 
signature and the expression of miRNAs could estimate 
the importance of these miRNAs expression in the 
pathogenesis and the treatment of DLBCL patients. The 
result of this novel approach may suggest new therapeutic 
strategies against DLBCL, throughout the development of 
miRNAs inhibitors of proangiomiRs or miRNAs mimics 
of antiangiomiRs.
RESULTS
The 84 DLBCL cases were classified according to 
the algorithm of Hans et al. [13]. 46.4% of the cases were 
identified as GCB, 36.9% as ABC (non-GCB) and 16.7% 
were unclassifiable. In the automated analysis of MVD, 
the results of CD34 expression were divided into quartiles 
according to the median number of CD34+ objects per 
100 μm2 TMA area, as shown below: Quartile I 24.93 to 
738.41; Quartile II 741.17 to 2522.48; Quartile III 2549.68 
to 5687.33; Quartile IV 6743.04 to 25424.57. In the manual 
analysis of MVD, the results of CD34 expression were also 
divided in quartiles, according to the median number of 
blood vessels by TMA area, as shown below: Quartile I 
12-71; Quartile II 71-104; Quartile III 105-136; Quartile 
IV 137-297. We found positive correlation (Pearson 
correlation coefficient, p=0.0163) between the assessment 
of MVD by the two methods. (Supplementary Figure 1). 
There was no statistically significant difference among the 
clinical variables gender, age, stage, IPI and molecular 
subtypes (Table 2) and according to their distribution 
in the groups with low MVD (quartiles I/II) and high 
MVD (quartiles III/IV) using the data obtained from the 
automated or the manual counting of MVD. Among the 84 
patients, 13 (15.5%) were treated with R-CHOP. The others 
received antracyclin-based regimen without rituximab. The 
small number of patients treated with R-CHOP is justified 
by the introduction of this standard therapy in the Brazilian 
Health System only in 2007 (most of our patients were 
diagnosed before this year).
Using the algorithm shown in Figure 1, 40% of the 
cases were classified as stromal-1, 50% as stromal-2 and 
10% were not classified. We could not find associations 
between stromal signatures and clinical variables.
We observed increased expression of proangiomiRs 
Let-7f, miR-17, miR-18a, miR-19b, miR-126, miR-130a, 
miR-210, miR-296 and miR-378 in 14%, 57%, 30%, 45%, 
12%, 12%, 56%, 58% and 48% of the cases, respectively. 
Among antiangiomiRs we found decreased expression 
of miR-16, miR-20b, miR-92a, miR-221 and miR-328 in 
27%, 71%, 2%, 44% and 11% of the cases, respectively 
(Figures 2 and 3).
We analyzed the correlation between the 
14 angiomiRs and clinical variables, molecular 
subtypes, MVD (automated and manual counting) and 
stromal signatures. We found association between the 
expression of two angiomiRs and the clinical variable 
age (< 60 years vs ≥ 60 years); increased expression of 
miR-296 and miR-20b was associated with age < 60 
Figure 1: Algorithm proposal for stromal signature classification, by immunohistochemistry. Abbreviations: 
SPARC = secreted protein, acidic and rich in cystein; stromal-1 and stromal-2 = stromal signatures; NC = not classified.
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years and age ≥ 60 years, respectively (Figures 4 and 5). 
No associations were found between the angiomiRs 
expression and the other clinical variables gender, 
staging and IPI.
Regarding the molecular subtypes, we found 
association between increased expression of three 
angiomiRs (miR-126, miR-130a and miR-328) and the 
subtype ABC (Figures 4 and 5).
We did not find statistically significant differences 
between the relative expression of the angiomiRs and 
the MVD evaluated by automated counting. However, 
we found expression values of the angiomiRs miR-
16, miR-221 and miR-328 compatible with the MVD 
evaluated by manual counting, i.e., higher levels of the 
three antiangiomiRs in the setting of cases classified as 
low MVD (quartiles I/II) (Figure 5). The Supplementary 
Figure 2 shows the expression level of angiomiRs 
(increased expression, decreased expression and normal 
expression), according to stromal-1 and stromal-2 
signatures.
We found statistically significant differences 
between the relative expression of angiomiRs Let-7f, miR-
126, miR-210, miR-378, miR-16, miR-221 and miR-328 
and the stromal-1 and stromal-2 signatures. However, only 
for miR-16, miR-221 and miR-328 we verified values 
of angiomiR expression compatible with the stromal 
signature, i.e., higher levels of antiangiomiRs on stromal-1 
signature (Figure 5).
Figure 2: Frequency of proangiomiRs expression (Let-7f, miR-17, miR-18a, miR-19b, miR-126, miR-130a, miR-210, 
miR-296 and miR-378) in 84 samples of DLBCL.
Figure 3: Frequency of antiangiomiRs expression (miR-16, miR-20b, miR-92a, miR-221 and miR-328) in 84 samples 
of DLBCL.
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The median overall survival of the 84 patients was 
not reached, with a maximum follow-up of 146.53 months. 
This fact has probably been due to the loss of follow-up of 
28 patients (33.3%). Of these, six patients (7.14%) were 
discharged after 5 years and returned to their hometown 
for follow-up. By the end of the study, 33 patients (39.3%) 
had died (survival from 0.63 to 74.67 months) and 23 
patients (27.4%) remained alive and receiving outpatient 
treatment (survival from 19.27 to 146.53 months). We 
found statistically significant differences when comparing 
Ann Arbor I/II with Ann Arbor III/IV stages (Log-rank 
test, p=0.0256). We also found a statistically significant 
difference when comparing the groups classified as low, 
intermediate and high International Prognostic Index 
Figure 5: AntiangiomiRs: A. Expression of miR-20b according to age at DLBCL diagnosis showed higher expression in patients 
aged >= 60 years (Mann-Whitney, p=0.0431); B. miR-328 expression according to molecular subtypes of Hans algorithm showing higher 
expression in ABC subtype (Mann-Whitney, p=0.0099); C. miR-16 expression in DLBCL according to CD34 (MVD - Manual counting) 
(p=0.0331, Mann-Whitney). The expression of CD34 (MVD) is ranked quartiles: I and II considered as low expression; III and IV 
considered as high expression. Number of cases examined = 80/84 (4 cases not available for CD34 expression); D. miR-16 expression in 
DLBCL according to stromal signature (p=0.0146, Mann-Whitney); E. miR-221 expression in DLBCL according to CD34 (MVD - manual 
counting) (p=0.0182, Mann-Whitney). The expression of CD34 (MVD) is ranked quartiles: I and II considered as low expression; III and 
IV considered as high expression. Number of cases analyzed = 80/84 (4 cases not available to CD34 expression); F. miR-221 expression 
in DLBCL according to stromal signature (p=0.0076, Mann-Whitney). G. Expression of miR-328 in DLBCL according to CD34 (MVD - 
manual counting) (p=0.0129, Mann Whitney). The expression of CD34 (MVD) is ranked quartiles: I and II considered as low expression; 
III and IV considered as high expression. Number of cases examined = 80/84 (4 cases not amenable for CD34 expression); H. miR-328 
expression in DLBCL according to stromal signature (p=0.0099, Mann-Whitney).
Figure 4: ProangiomiRs: A. Expression of miR-296 according to age at DLBCL diagnosis showed higher expression in patients 
aged <60 years (Mann-Whitney, p=0.0268); B. miR-126 expression according to molecular subtypes of Hans algorithm showing higher 
expression in ABC subtype (Mann-Whitney, p=0.0374); C. miR-130a expression according to molecular subtypes of Hans algorithm 
showing higher expression in ABC subtype (Mann-Whitney, p=0.0126).
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(Log-rank, p=0.0236). Another statistically significant 
difference was observed when comparing the MVD 
groups classified as quartiles I/II versus quartiles III/IV 
according to the automated counting (CD34+/100μm2).
(Table 3) No relevant difference in survival according to 
the stromal classification or clinical parameters was found 
(Figure 6).
We conducted multivariate analysis using the 
Cox regression model including variables such as 
staging, IPI and CD34 (automated counting), selected 
as important in survival in univariate analysis. IPI and 
CD34 confirmed independent impact on survival of the 
study group (p=0.044 and 0.048, respectively). Patients 
with high-risk IPI showed likelihood of evolving to death 
3.4 times higher than the rest of the group (95% CI 1.168 
to 9.938), while patients with higher MVD (quartiles III 
and IV) showed likelihood of evolving to death 2.0 times 
higher than the rest of the group (95% CI 1.008 to 4.193).
The angiomiRs identified as differentially expressed 
in DLBCL tissue (proangiomiRs miR-17, miR-210, miR-
296 and antiangiomiR miR-20b) were evaluated in an 
independent cohort of serum samples from patients with 
DLBCL at diagnosis and at the time of relapse. After 
evaluation of RNU44 (threshold cycle < 38), 6/10 (60%) 
controls, 21/39 (53.8%) DLBCL cases at diagnosis and 
7/19 (52.6%) relapsed DLBCL cases were considered 
Table 3: Overall survival analysis of patients included in the study
Variable N (%) Median Overall Survival 
(months)
p (Log-Rank)
Ann Arbor Staging
I/II 33 (39.3%) Not reached 0.0256
III/IV 51 (60.7%) 24.27
IPI
0-1 (low) 17 (20.5%) Not reached 0.0236
2-3 (intermediate) 46 (55.4%) Not reached
4-5 (high) 20 (24.1%) 8.47
Hans
GCB 39 (55.7%) Not reached 0.1472
ABC 31 (44.3%) 21.6
CD68
Low expression 20 (24,4%) Not reached 0.5965
High expression 62 (75.6%) 74.67
SPARC
Positive 32 (47.1%) Not reached 0.9378
Negative 36 (52.9%) Not reached
MVD — automated 
counting
Quartiles I/II 42 (50%) Not reached 0.0363
Quartiles III/IV 42 (50%) 23.9
MVD — manual counting
Quartiles I/II 40 (50%) Not reached 0.4041
Quartiles III/IV 40 (50%) Not reached
Stromal Signatures
Stromal-1 32 (44.4%) Not reached 0.6157
Stromal-2 40 (55.6%) Not reached
The variables include: Ann Arbor staging I/II vs III/IV, IPI low vs intermediate vs high, molecular subtypes-GCB vs non-
GCB or ABC, expression level of immunohistochemical markers CD68, SPARC, CD34 and stromal signatures
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Figure 6: A. Overall survival curve of the 84 patients included in the study. The median overall survival has not been reached, with a 
maximum follow-up of 146.53 months; B. Overall survival curve according to Ann Arbor Staging. The median overall survival in clinical 
stage I/II group has not been reached, while in the III/IV group was 24.27 months (log-rank, p=0.0256); C. Overall survival curve according 
to the International Prognostic Index (IPI). The median overall survival in the low and intermediate IPI groups was not achieved and 
was 8.47 months in the high IPI group (log-rank, p=0.0236; IPI 0-1: low; IPI 2-3: intermediate; IPI 4-5: high); D. Overall survival curve 
according to MVD (automated counting (CD34+/100μm2). The median overall survival in groups of quartiles I/II and quartiles III/IV has 
not been reached (log-rank, p=0.0363); E. Overall survival curve of the patients according to stromal signature. The median overall survival 
in the stromal-1 and stromal-2 groups was not reached (log-rank, p=0.6157).
Table 2: Clinical characteristics of patients, according to the classification in the molecular subtypes and cellular 
origin [13]
GCB ABC P
Gender
Female 19 (48.7%) 17 (54.8%) 0.6108
Male 20 (51.3%) 14 (45.2%)
Age
<60 years 17 (43.6%) 15 (48.4%) 0.6890
≥ 60 years 22 (56.4%) 16 (51.6%)
Ann Arbor Staging
I/II 17 (43.6%) 12 (38.7%) 0.6805
III/IV 22 (56.4%) 19 (61.3%)
IPI
0-1 (low) 11 (28.2%) 5 (16.1%) 0.3994
2-3 (intermediate) 18 (46.1%) 19 (61.3%)
4-5 (high) 9 (23.1%) 7 (22.6%)
Not assessed 1 (2.6%) 0
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valid for the miRNA expression evaluation. Although 
the four microRNAs seem to be important in DLBCL 
pathogenesis, no present difference was observed when 
the three groups of patients were analyzed (Supplementary 
Figure 3).
DISCUSSSION
In the present study, we classified DLBCL according 
to stromal-1 and stromal-2 signatures and evaluated the 
expression of miRNAs involved in angiogenesis, divided 
into proangiomiRs and antiangiomiRs. We observed 
correlation between the expression of stromal signatures 
and angiomiRs. Differentially expressed miRNAs can 
offer new possibilities of therapeutic interventions, 
especially considering that the same miRNA can 
potentially interfere in multiple oncogenic pathways 
[14, 15]. Besides, since angiogenesis is an important 
feature involved in the development and maintenance of 
malignant neoplasias, the data identified herein may be 
applicable to other types of cancer [16].
46.4% of the 84 DLBCL cases were classified as 
GCB subtype and 36.9% as ABC (non-GCB), similar to 
the report by Hans et al. [13]. Concerning the expression 
of CD34, we used two methods to analyze the MVD 
expression: automated and manual counting. For better 
classification, the results of CD34 expression with either 
the manual or the automated method were divided into 
quartiles, as done in other studies [17, 18]. We found a 
positive correlation between both methods and we stress 
that this is the first study that compares the evaluation 
of MVD by the two systems in DLBCL. We found 
no statistically significant difference between clinical 
variables and molecular subtypes, according to the 
patients’ distribution in low MVD (quartiles I/II) and high 
MVD (quartiles III/IV) neither in automated nor manual 
counting of MVD.
The stromal signatures were determined from 
gene expression and subsequently correlated with 
immunohistochemical markers [10]. In the present study, 
we chose SPARC (secreted protein, acidic and rich in 
cysteine) and CD68 as stromal-1 markers. Seeking the 
best alternative to classify cases according to the stromal 
signature, we made a third categorization using CD34, 
followed by SPARC and CD68 sequentially (Figure 1). 
We classified 40% as stromal-1, 50% as stromal-2 and 
10% as unclassified. Such effort minimized the percentage 
of cases that could not be classified and would not 
participate in further evaluations, including associations 
with angiomiRs. Although this sequential approach have 
not been described previously, it seems logical because the 
MVD manual counting correlated well with the automated 
counting, and SPARC and CD68 seem to identify the 
same population of cells. Another reason to use CD34 
as a starting point for the classification is our focus on 
epigenetic mechanisms of angiogenesis control. This way, 
we sought associations between the expression of the 
14 angiomiRs and clinical features, molecular subtypes, 
MVD and stromal signatures.
We also found increased expression of proangiomiR 
miR-130a in non-GCB patients. In the non-GCB DLBCL 
there is constitutional activation of the NF-kB pathway 
[19, 20]. Zhang et al. [21] observed that the increased 
expression of NF-kB or miR-130a promoted tumor growth. 
They described that TNF-α, NF-κB and miR-130a operate 
in negative feedback: lower TNF-α levels induce nuclear 
translocation of NF-kB, leading to increased expression 
of miR-130a. Therefore, the association observed in our 
study may be explained by the interaction between miR-
130a and NF-kB pathway. No direct association between 
increased expression of angiomiRs miR-126 and miR-328 
Table 1: Specifications of primary antibodies used in the TMA
Marker Clone Brand Dilution pH antigen 
retrieval
Time of antigen 
retrieval
Positive 
Control
CD10 56C6 mouse Dako 1:2 Tris-EDTA pH 9.0 20 min 97°C Palatine tonsil
BCL6 LN22 mouse Novocastra 1:100 CitratepH 6.1 20 min 97°C Palatine tonsil
MUM1 MUM1p mouse Novocastra 1:1200 CitratepH 6.1 20 min 97°C Palatine tonsil
CD68 KP1 mouse Dako 1:6000 CitratepH 6.1 20 min 97°C Palatine tonsil
SPARC H-90 Santa Cruz Biotechnology 1:500
Citrate
pH 6.1 20 min 97°C Kidney
CD34 QBEnd10 mouse Dako 1:800 CitratepH 6.1 20 min 97°C Prostate
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in non-GCB cases was found. We also did not find a good 
hypothesis for correlation between miR-296 or miR-20b 
and age at diagnosis.
There was a statistically significant difference 
between MVD and relative expression of angiomiRs 
miR-16, miR-221 and miR-328, with higher levels of 
these antiangiomiRs in situations of lower MVD. The 
same was confirmed for the three antiangiomiRs and the 
stromal signature, i.e., higher levels of antiangiomiRs in 
stromal-1 subtype. Therefore, technically, the two methods 
had confirmed results with similar meanings.
Analyzing overall survival according to the 
categories of each of the clinical or laboratory variables, 
we observed worse outcome in groups classified as Ann 
Arbor stage III/IV, high IPI and CD34 quartiles III/IV. IPI 
and CD34 confirmed independent impact on survival of 
the study group. Patients with high-risk IPI showed chance 
of evolving to death 3.4 times higher than the rest of the 
group, while patients with higher MVD showed chance 
of evolving to death 2.0 times higher than the rest of the 
group. Although all microRNAs evaluated here showed no 
prognostic significance, we can attribute this result in part 
to the fact of not having homogeneously treated patients 
(most of them did not receive R-CHOP).We still had a 
large percentage of patients discharged after five years 
of follow-up, which may have contributed to the median 
survival of the group had not been reached.
Because the proangiomiRs miR-17, miR-210 and 
miR-296 showed increased expression in 57%, 58% 
and 56% of the tumor samples, respectively, and the 
antiangiomiR miR-20b showed decreased expression in 
more than 50% of the tumor samples, these could be our 
target candidates for therapy. Using MiRTarBase (http://
mirtabase.mbc.nctu.edu.tw/php/search.php) we found 
the main targets related to the angiomiRs of interest 
detected in our study. From there, through STRING 
Protein Network Tool (http://string-db.org), we found 
the relationship of these angiomiRs targets involved 
in the same pathway. One example is the VEGF-A, 
HGS, CDKN1A and PTEN proteins. We observed that 
antagomiR miR-20b is involved in the regulation of 
genes belonging to the four exemplified networks. This 
demonstrates that the action of a miRNA in different 
pathways controls the normal functions of cells, which can 
simultaneously be deregulated in cancer.
Lei et al. [22] showed that miR-20b has an important 
biological role in tumor cells, promoting growth and 
survival of the tumor by controlling the oxygen supply. 
This mechanism occurs by decreasing the expression of 
HIF-1alpha and VEGF-A. Li et al. [23] studied patients 
with metastatic breast cancer and observed that VEGF-A 
and HIF-1alpha showed a higher level of expression in 
the group with high invasion, with negative correlation 
with miR-20b. Given the paucity of data in the literature 
regarding the function of miR-20b in cancer, it seems to 
be an interesting potential target in DLBCL. In addition, 
low miR-20b expression was related to low MVD and 
stromal-1 signature, although no correlation of this 
antiangiomiR with prognosis was observed.
High expression of miR-17 was found in several 
types of cancer, such as colorectal cancer, gastric cancer, 
hepatocellular carcinoma, glioma, basal cell carcinoma 
and pancreatic cancer. Zeng et al. [24] demonstrated 
that miR-17 was overexpressed in serum of patients with 
nasopharyngeal carcinoma. Wu et al. [25] showed that 
miR-17-5p acts as a proliferative factor for gastric cancer 
by inhibiting SOCS6 target. Qi et al. [26] evaluated the 
serum of patients with non-small cell lung cancer in 
initial stage and healthy donors and found that miR-17 
showed higher expression levels in patients in early stage. 
Therefore, it may be used as a biomarker in the diagnosis 
of early stage non-small cell lung cancer. Fang et al. [27] 
observed that miR-17-5p had significantly higher levels 
in patients with colorectal cancer in advanced clinical 
stages with metastasis. They also found that PTEN is 
the target of miR-17-5p in colon cancer cells and their 
interaction is responsible for multidrug resistance. Gao 
et al. [28] also showed correlation between miR-17 and 
PTEN in osteosarcoma and contribution of miR-17 in the 
progression and metastasis of this cancer type.
Zhan et al. [29] studied the serum levels of miR-210 
in patients with hepatocellular carcinoma who underwent 
arterial chemoembolization. They observed an increase 
in serum in the group with hepatocellular carcinoma, as 
well as a relationship between worse overall survival and 
increased serum levels after four weeks of treatment in 
refractory cases. Qu et al. [30] demonstrated that miR-
210 has upregulation in colorectal cancer, with higher 
expression levels correlating with larger tumor size, 
lymph node metastasis, advanced clinical stages and worse 
prognosis. Wang et al. [31] conducted a systematic review 
and meta-analysis to evaluate the role of the increase in 
miR-210 expression in the prognosis of some cancers 
(breast cancer, squamous cell carcinoma of head and neck, 
renal cancer, sarcoma soft tissue, pediatric osteosarcoma, 
bladder cancer and glioblastoma). They observed that the 
increased expression of miR-210 has a negative impact 
on disease-free survival, progression-free survival and 
relapse-free survival.
Conflicting results are reported regarding the role of 
miR-296 in carcinogenesis. Wei et al. [32] demonstrated 
that miR-296 regulates the HMGA1 expression in patients 
with prostate cancer, noting that high levels of HMGA1 
were associated with low expression levels of miR-296 
and strongly associated with more advanced disease 
stage. The increase in miR-296 expression significantly 
reduced cell proliferation and prostate cancer invasion. 
Lee et al. [33] also studied the miR-296 in prostate cancer, 
but having Pin1 as target; increased Pin1 expression 
is related to tumor development and poor prognosis in 
prostate cancer. They demonstrated that miR-296-5p has 
a tumor suppressor role, with potential prognostic effect. 
Hong et al. [34] investigated the expression of miR-296 
in esophageal squamous cell carcinoma and observed 
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increased expression in affected tissues with esophagitis, 
esophageal carcinoma in situ and esophageal squamous 
cell carcinoma. They demonstrated that the reduction of 
miR-296 expression rendered increased survival, even in 
patients with metastatic lymph node disease.
In the present work we identified potential 
angiomiRs candidates for targeted therapy. Depending on 
the function of the angiomiR, two antitumor therapeutic 
approaches may be used: antagomirs or microRNAs that 
mimic the lost function (mimics) [35–37]. We looked for 
proangiomiRs which had increased expression (above 
50%) (miR-17, miR-210 and miR-296), candidates to the 
antagomiR approach, trying to interrupt the angiogenesis 
process by inhibiting miRNA expression. Regarding to 
antiangiomiRs, miRNA mimics may be used to increase 
the expression of the miRNA of interest. MiR-20b was the 
only one to show decreased expression in more than 50% 
of DLBCL patients and it is likely an important target for 
clinical evaluation.
MATERIALS AND METHODS
Patients
We identified 124 patients treated at Sao Paulo 
Hospital between 2000 and 2010 whose paraffin blocks 
were available for immunohistochemical and molecular 
analysis. All 84 eligible cases were confirmed as DLBCL. 
We excluded nine HIV-positive cases, five T-cell/histiocyte 
DLBCL, 12 primary central nervous system and 14 cases 
that could not be “de novo” DLBCL. Demographic and 
clinical data, such as age, sex, histological diagnosis, 
Ann Arbor clinical stage and International Prognostic 
Index (IPI) were obtained from our databank and patients’ 
charts. This study was approved by Ethics Committee of 
Sao Paulo Hospital/UNIFESP (CEP 0002/11). Due to the 
retrospective characteristic of the study, written consent 
was not required.
Tissue microarray (TMA)
We constructed a tissue microarray (TMA) using 
paraffin blocks and Beecher Instruments equipment 
(Estigen, Tartu, Estonia). All H&E-stained DLBCL slides 
demonstrated more than 70% of tumor area, with no 
significant tissue necrosis. The samples were represented 
in duplicate in the receptor TMA block.
Immunohistochemical analysis (Table 1)
CD10, Bcl-6 and MUM-1 were used to classify 
cases according to their cellular origin [13]: 0 (0-10% 
positive cells); 1 (10-25%); 2 (25-50%); 3 (≥ 50%) 
(three slides of the TMA block for each marker were 
analyzed in duplicate). Expression of CD68 (same criteria 
above) and SPARC (< 5% negative and ≥ 5% positive) 
were used as stromal-1 markers [18]. To analyze the 
expression of CD34 (MVD, stromal-2), we performed 
automated and manual microvessel counting across the 
field of TMA. For automated analyses, we considered 
the number of CD34+ objects/100µm2 of TMA area. 
[Formula = (Microvessel Density - number of vessels per 
unit area (µm2) x Total Stain Area (µm2)/100], excluding 
areas inferior to 20µm2 [10]. In parallel, we conducted a 
manual counting of microvessels in the fullfield of TMA 
at 400X magnification. Those which appeared continuous 
microvessels were considered only once. Slide images 
were captured using ScanScope AT Turbo equipment 
(Aperio Technologies, Vista, CA, USA). Two independent 
observers classified slides using a semi-quantitative 
method (N.M.B. and A.C.A.).
microRNA extraction and qPCR reaction in 
paraffin embedded samples
miRNA extraction was performed using paraffin 
RecoverAll™ Total Nucleic Acid Isolation Kit for FFPE 
Tissues (Applied Biosystems, Foster City, CA). The 
quantitative real-time PCR was performed using TaqMan 
Assays Small RNA kit (Applied Biosystems, Foster City, 
CA). ProangiomiRs Let-7f (Assay ID 000382), miR-17 
(Assay ID 002308), miR-18a (Assay ID 002422), miR-19b 
(Assay ID 002425), miR-126 (Assay ID 002228), miR-
130a (Assay ID 000454), miR-210 (Assay ID 000512), 
miR-296 (Assay ID 000527) and miR-378 (Assay ID 
002243) and antiangiomiRs miR-16 (Assay ID 000391), 
miR-20b (Assay ID 001014), miR-92a (Assay ID 000431), 
miR-221 (Assay ID 000524) and miR-328 (Assay ID 
000543) were selected for analysis. U18 (Assay ID 
001204) and RNU44 (Assay ID 001094) were used 
to normalize reactions. Nine palatine tonsils samples 
served as negative controls. MicroRNAs were considered 
differentially expressed when levels of tumor samples 
were 1.2-fold higher or lower than control samples using 
2-ΔΔCt formula [38].
microRNA extraction and qPCR reaction in 
serum samples
We extracted total RNA from 200µL of serum (in 
duplicates) of 10 control samples from normal healthy 
individuals, 39 samples from patients with DLBCL at 
diagnosis and 19 samples from patients with DLBCL at 
the time of relapse, using miRNeasy Serum/plasma Kit 
(Qiagen, Dossseldorf, Germany). We determined the 
concentration of the extracted total RNA from serum 
samples using the DeNovix DS-11 spectrophotometer. 
10ng of total RNA was used for cDNA synthesis with 
TaqMan Assays Small RNA kit (Applied Biosystems, 
Foster City, CA). The expression of RNU44 was used as 
calibrator for the qPCR, using 7500 Real Time System 
(Applied Biosystems, Foster City, CA). Samples with CT 
value greater than 38 were considered negative, according 
to Song et al. [39].
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Statistical analysis
The associations between the variables of interest 
were tested with the chi-square test (or Fisher’s exact 
test). To estimate the significance of the difference 
between the mean or median we performed the t test 
(unpaired or Mann-Whitney, respectively) or the analysis 
of variance (OneWay ANOVA with Post Hoc Test or 
OneWay ANOVA with Tukeys’s Multiple Comparison 
test). The Pearson correlation was used to analyze 
possible continuous numerical associations. Overall 
survival was calculated as the time between start of 
treatment and death related to the disease. Deaths not 
related to the disease or dropouts were censored. The 
overall survival curves were made according to the 
Kaplan-Meier method and compared using the log-rank 
test. For all statistical tests, the significance level of 5% 
(α=5%) was used. Statistical analysis was performed 
with SPSS version 8.0 for Windows. The gene expression 
graphs were constructed with the GraphPad Prism version 
5.0 (www.graphpad.com).
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